2. Academic Validation
  3. A dual PROTAC nanocarrier amplifies DNA damage and STING activation for cancer immunotherapy

A dual PROTAC nanocarrier amplifies DNA damage and STING activation for cancer immunotherapy

  • J Control Release. 2025 Oct 2;388(Pt 1):114290. doi: 10.1016/j.jconrel.2025.114290.
Hangyu Zhou 1,  Xueping Luo 1,  Chuyu Huang 2,  Yixin Liu 1,  Qiuyuan Li 2,  Guangmiao Chen 2,  Rongrong Zheng 2,  Shiying Li 3,  Linping Zhao 4
Affiliations

Affiliations

  • 1 Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, the NMPA and State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 510700, PR China.
  • 2 Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, PR China.
  • 3 Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, PR China. Electronic address: lisy-sci@gzhmu.edu.cn.
  • 4 Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, the NMPA and State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 510700, PR China; Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, PR China. Electronic address: zlp2022@gzhmu.edu.cn.
PMID: 41045969 DOI: 10.1016/j.jconrel.2025.114290
Abstract

The cytoplasmic accumulation of damaged DNA to activate the STING pathway has emerged as a promising strategy to enhance tumor immunogenicity and improve the efficacy of immune checkpoint blockade (ICB) therapy. Herein, a stimuli-responsive and dual PROTAC-embedded immunoactivator (denoted as Sd@Lip) is developed to potentiate ICB through amplified DNA damage and robust STING activation. Sd@Lip comprises an acid-sensitive liposomal nanocarrier co-encapsulating two targeted degraders of dBET1 (a BRD4 Degrader) and SK-575 (a PARP1 Degrader), which enhances drug solubility, stability, and enable precise stoichiometric co-delivery. Mechanistically, Sd@Lip enhances DNA damage by simultaneously disrupting both nonhomologous end joining (NHEJ) and homologous recombination (HR) repair pathways, leading to cytoplasmic DNA accumulation that activates STING signaling, induces proinflammatory cytokine release and enhances infiltration of immune effector cells. This immunogenic cascade promotes the recruitment of natural killer (NK) cells and cytotoxic T lymphocytes into the tumor microenvironment, thereby significantly augmenting the therapeutic efficacy of ICB against both primary and metastatic breast tumors. Collectively, this study highlights a synergistic PARP1 and BRD4 degradation strategy to induce immunostimulatory DNA damage, offering a compelling approach to improve outcomes in breast Cancer Immunotherapy.

Keywords

DNA damage; Drug delivery; Immunotherapy; PROTAC; STING activation.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z